This press release contains forward-looking statements.

Boston Scientific wishes to of this press release this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected are among others, risks associated with new product development and marketing related clinical trials, intellectual property, regulatory approvals, offers of competition, integration of acquired companies, Boston Scientific ‘s overall business strategy, and other factors described in Boston Scientific’s filings with the Securities and Exchange Commission..

MicroRNA regulation hESC fates, Yale University, New Haven, Principal Investigator,Molecular Profiling and the fate of the cell potential of hES – derived early neural crest precursors, Yale University, New Haven, Mart n I Garc a – Castro, principal Investigator,Neural Stem Cell Responses to hypoxia, Yale University, New Haven, Principal Investigator,, induction and differentiation of beta-cells from human embryonic stem cells, Yale University, New Haven, Kevan Herold Analysis of homologous recombination in embryonic stem cells and stimulation with viral proteins, University of Connecticut Health Center, Farmington, April Schumacher, Principal Investigator..Treatment as prevention model has been announced by UNAIDS and the World Health Organisation Within these the treatment 2.0 the initiative last year way a central pillar of global strategy been incorporated of reacting the HIV.

These findings a true scientific breakthrough and be a game changer in the reply to HIV, said Michelstadt Sidib, Executive Director of the Joint United Nations Programme on on HIV / AIDS ? We need treat a prevent as a part of combination therapy prevention strategy BC – our shared vision out of to zero newly infected and null deaths from AIDS embracing. .

Related Posts

Other Posts From Category "rehabilitation":